Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Burden of Cardiovascular Disease in Lymphoma Survivors: A Population-Based Matched Cohort Study.

JACC. Advances·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Sex-Specific Associations between Long-term Air Pollution Exposure and Coronary Atherosclerosis at Cardiac CT.

Radiology·2026
Same author

Field strength dependence, physiologic correlates, and prognostic significance of ventricular blood pool T2 mapping on cardiovascular magnetic resonance imaging.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same author

Machine Learning Model Using Pre-Cancer Therapy Cardiac Magnetic Resonance Images to Predict Cancer Therapy-Related Cardiac Dysfunction.

JACC. Cardiovascular imaging·2026
Same journal

Sacubitril/Valsartan in Anthracycline-Treated Patients: A Systematic Review and Meta-Analysis of Available Evidence.

JACC. CardioOncology·2026
Same journal

Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework: JACC Cardio-Oncology Primer.

JACC. CardioOncology·2026
Same journal

Correction.

JACC. CardioOncology·2026
Same journal

In Memoriam: Dr Eugene Braunwald, MD, MACC.

JACC. CardioOncology·2026
Same journal

Exploring Overlooked Mediators Linking Myocardial Infarction to Hematologic Malignancies.

JACC. CardioOncology·2026
Same journal

Refining Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction.

JACC. CardioOncology·2026
See all related articles
  1. Home
  2. Reply: Refining Vascular Biomarker-guided Risk Stratification For Cancer Therapy-related Cardiac Dysfunction
  1. Home
  2. Reply: Refining Vascular Biomarker-guided Risk Stratification For Cancer Therapy-related Cardiac Dysfunction

Related Experiment Videos

REPLY: Refining Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction

Priya Mistry, Dakota Gustafson, Paaladinesh Thavendiranathan

    JACC. Cardiooncology
    |June 17, 2026
    Summary

    No abstract available in PubMed .

    Related Experiment Videos